Pharmacokinetics of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol and its active metabolite after oral and intravenous administration in rat

Xenobiotica

Volumn 39, Issue 6, 2009, Pages 457-464

  Zhang, X ^a   Xu, J ^a   Zhang, D ^b   Gu, J ^b   Zhao, Y ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

12 ; 20(S) 25 methoxyl dammarane 3 ; 20 triol (25 OCH 3 PPD); 25 OH PPD; Active metabolite; Liquid chromatography tandem mass spectroscopy (HPLC MS MS); Pharmacokinetics

Indexed keywords

20(S) 25 METHOXYL DAMMARANE 3BETA, 12 BETA, 20 TRIOL; ANTINEOPLASTIC AGENT; DRUG METABOLITE; PLANT EXTRACT; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; 25 METHOXYDAMMARANE 3,12,20 TRIOL; 25-METHOXYDAMMARANE-3,12,20-TRIOL; TRITERPENE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOASSAY; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; REPRODUCIBILITY; TIME; WISTAR RAT;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL ASSAY; FEMALE; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRITERPENES;

EID: 69249208641     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902810951     Document Type: Article

References (27)

1. Attele AS, Wu JA, Yuan CS. (1999). Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58:1685-1693
2. Bae EA, Han MJ, Choo MK, Park SY, Kim DH. (2002). Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharmaceut Bull 25:58-63.
3. Bionda C, Athias A, Poncet D, Alphonse G, Guezguez A, Gambert P, Rodriguez-Lafrasse C, Ardail D. (2008). Oxidation of 5-methoxy- N, N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 75:752-760
4. Cai Z, Qian T, Wong RN, Jiang Z. (2003). Liquid chromatography- electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3. Analytica Chimica Acta 492:283-293
5. Cheng LQ, Na JR, Bang MH, Kim MK, Yang DC. (2008). Conversion of major ginsenoside Rb1 to 20(S)-ginsenoside Rg3 by Microbacterium sp. GS514. Phytochemistry 69:218-224
6. Hasegawa H. (2004). Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 95:153-157
7. Lee PS, Han JY, Song TW, Sung JH, Kwon O, Song S, Chung YB. (2006). Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with d£-cyclodextrin. Int J Pharmaceut 316:29-36.
8. Li G, Wang Z, Sun Y, Liu K, Wang Z. (2006). Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells. Basic Clin Pharmacol Toxicol 98:588-592
9. Li K, Chen X, Xu J, Li X, Zhong D. (2005). Liquid chromatography/ tandem mass spectrometry for pharmacokinetic studies of 20 (R)-ginsenoside Rg3 in dog. Rapid Comm Mass Spectrom 19:813-817
10. Li L, Sheng Y, Zhang J, Wang C, Guo D. (2004). HPLC determination of four active saponins from Panax notoginseng in rat serum and its application to pharmacokinetic studies. Biomed Chromatogr 18:849-856 (Pubitemid 40089858)
11. Narimatsu S, Yonemoto R, Masuda K, Katsu T, Asanuma M, Kamata T, Katagi M, Tsuchihashi H, Kumamoto T, Ishikawa T, Naito S, Yamano S, Hanioka N. (2008). Oxidation of 5-methoxy-N, N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 75:752-760
12. Paek IB, Moon Y, Kim J, Ji HY, Kim SA, Sohn DH, Kim JB, Lee HS. (2006). Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharmaceut Drug Disposit. 27:39-45.
13. Qian T, Cai Z, Wong RN, Jiang ZH. (2005a). Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Comm Mass Spectrom 19:3549-3554
14. Qian T, Cai Z, Wong RN, Mak NK, Jiang ZH. (2005b). In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B 816:223-232
15. Qian T, Jiang ZH, Cai Z. (2006). High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Anal Biochem 352:87-96.
16. Sanderson L, Taylor G W, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM. (2004). Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin after intraperitoneal administration to mice. Drug Metab Disposit 31:1065-1071
17. Sparreboom A, Cox MC, Acharya MR, Figg WD. (2004). Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489-2503 (Pubitemid 41115408)
18. Sun J, Wang G, Haitang X, Hao L, Guoyu P, Tucker I. (2005). Simultaneous rapid quantification of ginsenoside Rg1 and its secondary glycoside Rh1 and aglycone protopanaxatriol in rat plasma by liquid chromatography-mass spectrometry after solid-phase extraction. J Pharmaceut Biomed Anal 38:126-132
19. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. (2003). Degradation of ginsenosides in humans after oral administration. Drug Metab Disposit 31:1065-1071
20. Wang W, Wang G, Xie H, Sun J, Zhao S, Jiang X, Li H, Lv H, Xu M, Wang R. (2007a). Determination of ginsenoside Rd in dog plasma by liquid chromatography-mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies. J Chromatogr B 852:8-14. (Pubitemid 46839207)
21. Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. (2008). (20(S)-25-methoxyl-dammarane-3d£, 12d£, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer 98:792-802.
22. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. (2007b). In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 59:589-601.
23. Xie HT, Wang GJ, Lv H, Sun RW, Jiang XL, Li H, Wang W, Huang CR, Xu MJ. (2005a). Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs. Eur J Drug Metab Pharmacokinet 30:63-67
24. Xie HT, Wang GJ, Sun JG, Tucker I, Zhao XC, Xie YY, Li H, Jiang XL, Wang R, Xu MJ, Wang W. (2005b). High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solidphase extraction for pharmacokinetic studies. J Chromatogr B 818:167-173
25. Xu QF, Fang XL, Chen DF. (2003). Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 84:187-192
26. Zhang X, Zhang D, Xu J, Gu J, Zhao Y. (2007). Determination of 25-OH-PPD in rat plasma by high-performance liquid chromatography -mass spectrometry and its application in rat pharmacokinetic studies. J Chromatogr B 858:65-70. (Pubitemid 47513608)
27. Zhao Y, Wang W, Han L, Rayburn ER, Hill DL, Wang H, Zhang R. (2007). Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3d£, 12d£, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng. Med Chem 3:51-60.